Xenon Pharmaceuticals Inc. (XENE) Q1 2019 Earnings Results

Xenon Pharmaceutical Misses on EPS, Stock Down 2.46%

Xenon Pharmaceutical's earnings report shows a loss per share of $0.42, with no revenue figures disclosed. The stock reacted negatively, dropping 2.46%, likely due to the lack of guidance and clarity on financial performance. Investors may be concerned about the company's future prospects without specific revenue targets or updates on their clinical programs.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.42	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious approach, emphasizing the importance of their ongoing clinical trials. They did not offer specific guidance or revenue expectations.

Management did not provide specific revenue figures or guidance for the upcoming quarters.

The focus remains on advancing their clinical programs.

Xenon Pharmaceutical Misses on EPS, Stock Down 2.46%

Key numbers

Management commentary

Xenon Pharmaceuticals Inc.

More earnings this week

Xenon Pharmaceutical Misses on EPS, Stock Down 2.46%

Key numbers

Management commentary